FDA granted marketing authorization to the Parsortix System for the harvesting of circulating cancer tumor cells in metastatic breast cancer.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
FDA grants marketing authorization to Parsortix System for liquid biopsy in MBC
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.
New data indicate that, professional guidelines notwithstanding, doctors rarely address concerns about sexual health when they treat women with cancer.
Six Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium scientists received $1.7M in grants from Breast Cancer Research Foundation to launch or continue studies aimed at improving outcomes in breast cancer.
FDA approved Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is taking place both virtually and at the George R. Brown Convention Center in...
